Johnson & Johnson (JNJ) is 'absolutely' a buy - Cramer
Tweet
Share
E-mail
Get Alerts JNJ Hot Sheet
Join SI Premium – FREE
On CNBC, Jim Cramer said Johnson & Johnson (NYSE: JNJ) is 'absolutely' a buy on earnings, cash flow, the balance sheet, the buyback, and the dividend.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA: issues early alert on Abiomed heart pump controller purge cassette issue
- Electra Therapeutics files for proposed IPO
- AiRWA receives Nasdaq deficiency notice over late 10-K filing
Create E-mail Alert Related Categories
Trader TalkRelated Entities
Jim Cramer, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
